Advertisement

Drugs

, Volume 73, Issue 4, pp 341–356 | Cite as

Targeting Interleukin-6 in Rheumatoid Arthritis

  • Md Yuzaiful Md Yusof
  • Paul EmeryEmail author
Review Article

Abstract

Interleukin (IL)-6 is a potent pro-inflammatory agent that plays a crucial role in the pathogenesis of systemic inflammatory disease. Targeting this pathway in rheumatoid arthritis (RA) seems an attractive option as IL-6 is important for both joint destruction and systemic manifestations. Currently, tocilizumab, which binds the IL-6 receptor, is licensed for treatment in active, moderate to severe disease in RA and systemic juvenile idiopathic arthritis (JIA). Several other promising IL-6 blocking agents as well as a subcutaneous form of tocilizumab are currently undergoing phase III clinical trials. The aim of this article is to provide an up-to-date analysis of clinical efficacy and tolerability data concerning the use of IL-6 inhibitors. Data from clinical trials demonstrated that clinical efficacy for tocilizumab, which included improvement in physical function and halting radiographic progression, were comparable to other biologics licensed for use in RA. Patients who should gain most are RA patients with systemic features such as high inflammatory markers and anaemia. Perhaps, the strongest selling point lies in its effectiveness as a monotherapy. This is particularly useful in those who are not tolerating combination treatment with methotrexate. Tocilizumab is one of a few biologics that have been shown to be superior to methotrexate in head-to-head studies. The safety profile of tocilizumab also is comparable to other currently available biologics. There is a small but significant increase in adverse events including infections in patients treated with tocilizumab compared to placebo, particularly in patients who are elderly and those with multiple comorbidities. Elevated lipid profiles are frequent but have not been associated with major cardiovascular events. IL-6 blockade is a major advancement in the treatment of RA as it targets a unique molecule. Over the next few years, evidence will be available on the long-term cardiovascular safety and efficacy of subcutaneous IL-6 blocking agents.

Keywords

Rheumatoid Arthritis Patient Juvenile Idiopathic Arthritis Tocilizumab Tumour Necrosis Factor Inhibitor Radiographic Progression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

Md Yuzaiful Md Yusof: no conflicts of interest. Paul Emery: consulting fees from Pfizer, Merck, Abbott, BMS and UCB. No funding involved.

References

  1. 1.
    Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27(2):269–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003;21(5):S154–7.PubMedGoogle Scholar
  3. 3.
    Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;22:1586–93.CrossRefGoogle Scholar
  4. 4.
    Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study—a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.PubMedCrossRefGoogle Scholar
  5. 5.
    Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–23.PubMedCrossRefGoogle Scholar
  7. 7.
    Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2(5):247–56.PubMedCrossRefGoogle Scholar
  8. 8.
    Hibi M, Murakami M, Saito M, et al. Molecular-cloning and expression of an IL-6 signal transducer, GP130. Cell. 1990;63(6):1149–57.PubMedCrossRefGoogle Scholar
  9. 9.
    Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, GP130. Cell. 1989;58(3):573–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Rose-John S, Scheller J, Elson G, et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227–36.PubMedCrossRefGoogle Scholar
  12. 12.
    Muraguchi A, Hirano T, Tang B, et al. The essential role of B-cell stimulatory factor-II (BSF-2/IL-6) for the terminal differentiation of B-cells. J Exp Med. 1988;167(2):332–44.PubMedCrossRefGoogle Scholar
  13. 13.
    Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis. 2011;2011:765624.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhou L, Ivanov II, Spolski R, et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Madhok R, Crilly A, Watson J, et al. Serum interleukin-6 levels in rheumatoid arthritis—correlations with clinical and laboratory indexes of disease activity. Ann Rheum Dis. 1993;52(3):232–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Sack U, Kinne R, Marx T, et al. Interleukin-6 in synovial-fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int. 1993;13(2):45–51.PubMedCrossRefGoogle Scholar
  17. 17.
    Maruotti N, Cantatore FP, Crivellato E, et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol. 2006;21(4–6):557–66.PubMedGoogle Scholar
  18. 18.
    Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165–76.PubMedCrossRefGoogle Scholar
  19. 19.
    Palmqvist P, Persson E, Conaway HH, et al. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol. 2002;169(6):3353–62.PubMedGoogle Scholar
  20. 20.
    Ohta S, Imai K, Yamashita K, et al. Expression of matrix metalloproteinase 7 (matrilysin) in human osteoarthritic cartilage. Lab Investig. 1998;78(1):79–87.PubMedGoogle Scholar
  21. 21.
    Okada Y, Gonoji Y, Nakanishi I, et al. Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59(5):305–12.PubMedCrossRefGoogle Scholar
  22. 22.
    Chrousos GP. Seminars in medicine of the Beth-Israel-Hospital, Boston—the hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Yoshio-Hoshino N, Adachi Y, Aoki C, et al. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res. 2007;67(3):871–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Kaly L, Rosner I. Tocilizumab—a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol. 2012;26(1):157–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Burmester GR, Rubbert-Roth A, Cantagrel AG, et al. A randomized, double-blind, parallel group study of the safety and efficacy of tocilizumab SC versus tocilizumab IV, in combination with traditional Dmards in patients with moderate to severe RA. Arthritis Rheum. 2012;64(10):S1075.Google Scholar
  27. 27.
    Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817–29.PubMedCrossRefGoogle Scholar
  28. 28.
    Smolen JS, Schoels M, Nishimoto N, Breedveld FC, Burmester G, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. Epub 30 Jan 2013.Google Scholar
  29. 29.
    Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease. Int Med. 2007;46(11):771–4.CrossRefGoogle Scholar
  30. 30.
    Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. Swiss Medical Wkly. 2011;141:w13156.Google Scholar
  31. 31.
    Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res. 2012;64(11):1720–9.CrossRefGoogle Scholar
  32. 32.
    Puechal X, de Bandt M, Berthelot J, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res. 2011;63(1):155–9.CrossRefGoogle Scholar
  33. 33.
    Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Sumida K, Ubara Y, Suwabe T, et al. Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology. 2011;50(10):1928–30.PubMedCrossRefGoogle Scholar
  35. 35.
    Shapiro LS, Farrell J, Haghighi AB. Tocilizumab treatment for neuro-Behcet’s disease, the first report. Clin Neurol Neurosurg. 2012;114(3):297–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Hirano T, Ohguro N, Hohki S, et al. A case of Behcet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22(2):298–302.PubMedCrossRefGoogle Scholar
  37. 37.
    Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology. 2010;49(12):2408–12.PubMedCrossRefGoogle Scholar
  38. 38.
    Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology. 2011;50(7):1344–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Genovese MC, Kivitz AJ, Simon Campos AJ, et al. Sarilumab for the treatment of moderate-to-severe rheumatoid arthritis: results of a phase 2, randomized, double-blind, placebo-controlled, international study. Arthritis Rheum. 2011;63(12):4041–2.CrossRefGoogle Scholar
  40. 40.
    Mease P, Strand V, Dimic A, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012;71(7):1183–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Hsu B, Sheng S, Smolen JS, et al. Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 monoclonal antibody, in active rheumatoid arthritis patients despite methotrexate therapy. Arthritis Rheum. 2011;63(10)Google Scholar
  42. 42.
    Fleischmann R, Kivitz AJ, Wagner F, et al. A pilot study investigating the tolerability and pharmacodynamic effect of single intravenous/subcutaneous doses of olokizumab, an anti-interleukin-6 monoclonal antibody, in patients with rheumatoid arthritis. Arthritis Rheum. 2012; 64(10).Google Scholar
  43. 43.
    Nishimoto N, Kazuyuki Y, Nobuyuki M, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody—a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.PubMedCrossRefGoogle Scholar
  45. 45.
    Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic, and immunogenic effects after 1 year of tocilizumab-based treatment strategy with and without methotrexate in rheumatoid arthritis: the ACT-RAY study. Arthritis Rheum. 2012;64(10):S1077–8.Google Scholar
  47. 47.
    Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580–4.PubMedCrossRefGoogle Scholar
  49. 49.
    Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–97.PubMedCrossRefGoogle Scholar
  50. 50.
    Yazici Y, Curtis JR, Ince A, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71(2):198–205.PubMedCrossRefGoogle Scholar
  51. 51.
    Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968–80.PubMedCrossRefGoogle Scholar
  52. 52.
    Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609–21.PubMedCrossRefGoogle Scholar
  53. 53.
    Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796–806.PubMedCrossRefGoogle Scholar
  54. 54.
    Mierau M, Schoels M, Gona G, et al. Assessing remission in clinical practice. Rheumatology. 2007;46(6):975–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Dinarello CA, Cannon JG, Wolff SM, et al. Tumor-necrosis-factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med. 1986;163(6):1433–50.PubMedCrossRefGoogle Scholar
  56. 56.
    Brennan FM, Jackson A, Chantry D, et al. Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2(8657):244–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Gaujoux-Viala C, Mouterde G, Baillet A, et al. Evaluating disease activity in rheumatoid arthritis: Which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine. 2012;79(2):149–55.PubMedCrossRefGoogle Scholar
  58. 58.
    Matsui T, Kuga Y, Nishino J, et al. Comparison of composite disease activity indices for rheumatoid arthritis. Mod Rheumatol. 2011;21(2):134–43.PubMedCrossRefGoogle Scholar
  59. 59.
    Kaneko A, Kida D, Saito K, et al. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol Int. 2012;32(11):3631–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 2011;63(1):43–52.PubMedCrossRefGoogle Scholar
  61. 61.
    Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–23.PubMedCrossRefGoogle Scholar
  62. 62.
    Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappa B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000;43(2):259–69.PubMedCrossRefGoogle Scholar
  63. 63.
    Conaghan PG, Peterfy CG, DiCarlo J, et al. Early reductions in tissue inflammation with tocilizumab as either monotherapy or in combination with methotrexate: 12-week unblinded results from a magnetic resonance imaging substudy of a randomized controlled trial. Arthritis Rheum. 2011;63(10):S165–6.Google Scholar
  64. 64.
    Fries JF, Ramey DR. ‘‘Arthritis specific’’ global health analog scales assess ‘‘generic’’ health related quality-of-life in patients with rheumatoid arthritis. J Rheumatol. 1997;24(9):1697–702.PubMedGoogle Scholar
  65. 65.
    Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res. 1992;5(3):119–29.PubMedCrossRefGoogle Scholar
  66. 66.
    Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141.PubMedCrossRefGoogle Scholar
  67. 67.
    Kobayashi K, Okamoto Y, Inoue H, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Int Med. 2009;48(15):1307–9.CrossRefGoogle Scholar
  68. 68.
    Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology. 2011;50(3):552–62.PubMedCrossRefGoogle Scholar
  69. 69.
    Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [published erratum appears in JAMA 2006;295(21):2482]. JAMA. 2006;295(19):2275–85.PubMedCrossRefGoogle Scholar
  70. 70.
    Suwa T, Hogg JC, English D, et al. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol. 2000;279(6):H2954–60.PubMedGoogle Scholar
  71. 71.
    Ash Z, Emery P. The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther. 2012;12(9):1277–89.PubMedCrossRefGoogle Scholar
  72. 72.
    Myasoedova E, Crowson CS, Kremers HM, et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010;69(7):1310–4.PubMedCrossRefGoogle Scholar
  73. 73.
    van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88(7):3005–10.PubMedCrossRefGoogle Scholar
  74. 74.
    Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy—analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886–95.PubMedCrossRefGoogle Scholar
  75. 75.
    Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70:I104–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell. 2011;19(4):429–31.PubMedCrossRefGoogle Scholar
  77. 77.
    Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology. 2012;51:V38–47.PubMedCrossRefGoogle Scholar
  78. 78.
    Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis. 2010;69(9):1691–3.PubMedCrossRefGoogle Scholar
  79. 79.
    Burmester GR, Feist E, Kellner H, et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011;70(5):755–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low—results from RABBIT, the German biologics register. Arthritis Res Ther. 2006;8(3):R66.PubMedCrossRefGoogle Scholar
  81. 81.
    Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(4):583–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Kavanaugh A, Emery P, van Vollenhoven RF, et al. Tocilizumab monotherapy compared with adalimumab monotherapy in patients with rheumatoid arthritis: results of a 24-week study. Arthritis Rheum. 2012;64(10):S333–4.Google Scholar
  83. 83.
    Haque S, Mirjafari H, Bruce IN. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol. 2008;19(4):338–43.PubMedCrossRefGoogle Scholar
  84. 84.
    Kerola AM, Kauppi MJ, Kerola T, et al. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? Ann Rheum Dis. 2012;71(10):1606–15.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular MedicineUniversity of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching HospitalsLeedsUK

Personalised recommendations